Non-small cell lung cancer+1
Not recruitingStudy on Brigatinib and Durvalumab for Patients with Unresectable Stage III Non-Small Cell Lung Cancer with ALK Gene Change After Chemotherapy and Radiation Therapy
Study on Brigatinib and Durvalumab for Patients with Unresectable Stage III Non-Small Cell Lung Cancer with ALK Gene Change After Chemotherapy and Radiation Therapy
- Disease:Non-small cell lung cancerNon-small cell lung cancer stage III
- Substances:BrigatinibDurvalumab
Italy- Participants:18–64 years · 65+ years
- Substances:Brigatinib
- Sponsor:ETOP IBCSG Partners Foundation










